Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Increase in calcidiol level is associated with improved sternal bone healing after cardiac surgery with sternotomy-REINFORCE-D trial results

D. Černý, M. Čečrle, E. Sedláčková, B. Míková, E. Drncová, I. Skalský, M. Mieresová, M. Halačová

. 2025 ; 26 (1) : 224. [pub] 20250623

Language English Country England, Great Britain

Document type Journal Article, Randomized Controlled Trial

Persistent link   https://www.medvik.cz/link/bmc25015273

INTRODUCTION: Heart surgery is associated with a sternotomy in most patients. Low serum calcidiol level below 80 nmol/l carries the risk of bone loss as a risk factor in sternotomy healing. OBJECTIVES: The primary objective was to compare postoperative complications of sternotomy healing in two groups of patients treated with cholecalciferol or placebo. Secondary objectives were focused on the degree of sternal healing, length of hospitalization, number of days spent in ICU and mechanical ventilation, and number of repeated hospitalizations for sternotomy complications. METHODOLOGY: Monocentric, randomized, double-blind, placebo-controlled, prospective study was conducted from September 2016 to December 2020 at Na Homolce Hospital. Of the 216 originally recruited and randomized subjects, 141 completed the study. Seventy-two subjects were enrolled in the cholecalciferol arm, and sixty-nine subjects in the placebo arm. The detailed methodology has been published previously. The results are presented as a comparison between two groups: calcidiol above 80 nmol/l (saturated subjects) and the calcidiol lower or equal to 80 nmol/l (unsaturated subjects). RESULTS: Statistics include 141 subjects. After a 6-month follow-up, CT imaging and calcidiol levels were performed. PRIMARY OBJECTIVE: postoperative complications in sternotomy were not among the population under or above 80 nmol/l statistical difference (p = 0.907). SECONDARY OBJECTIVES: monitored parameters did not differ between individual arms. But the key was the state of saturation with calcidiol (> 80 nmol/l), which was associated with a significantly lower risk of complete non-healed sternotomy (p = 0.008). CONCLUSION: Optimal calcidiol level (> 80 nmol/l) indicates a positive trend towards greater sternal healing. Cholecalciferol oral administration can be considered as a safe method how to achieve the required calcidiol concentration. TRIAL REGISTRATION: EU Clinical Trials Register, EUDRA CT No: 2016-002606-39.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015273
003      
CZ-PrNML
005      
20250731090902.0
007      
ta
008      
250708s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13063-025-08786-x $2 doi
035    __
$a (PubMed)40551234
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Černý, Dalibor $u Department of Clinical Pharmacy, Na Homolce Hospital, Prague, Czech Republic. dalibor.cerny@seznam.cz $u Institute of Pharmacology, First Faculty of Medicine, Charles University in Prague, Albertov 4, Prague, 12800, Czech Republic. dalibor.cerny@seznam.cz $u Department of Clinical Pharmacy, Regional Hospital Liberec, Liberec, Czech Republic. dalibor.cerny@seznam.cz $u Institute of Biomedicine and Radiology, Faculty of Health Studies, Technical University of Liberec, Liberec, Czech Republic. dalibor.cerny@seznam.cz $1 https://orcid.org/0000000188925996 $7 jx20101201018
245    10
$a Increase in calcidiol level is associated with improved sternal bone healing after cardiac surgery with sternotomy-REINFORCE-D trial results / $c D. Černý, M. Čečrle, E. Sedláčková, B. Míková, E. Drncová, I. Skalský, M. Mieresová, M. Halačová
520    9_
$a INTRODUCTION: Heart surgery is associated with a sternotomy in most patients. Low serum calcidiol level below 80 nmol/l carries the risk of bone loss as a risk factor in sternotomy healing. OBJECTIVES: The primary objective was to compare postoperative complications of sternotomy healing in two groups of patients treated with cholecalciferol or placebo. Secondary objectives were focused on the degree of sternal healing, length of hospitalization, number of days spent in ICU and mechanical ventilation, and number of repeated hospitalizations for sternotomy complications. METHODOLOGY: Monocentric, randomized, double-blind, placebo-controlled, prospective study was conducted from September 2016 to December 2020 at Na Homolce Hospital. Of the 216 originally recruited and randomized subjects, 141 completed the study. Seventy-two subjects were enrolled in the cholecalciferol arm, and sixty-nine subjects in the placebo arm. The detailed methodology has been published previously. The results are presented as a comparison between two groups: calcidiol above 80 nmol/l (saturated subjects) and the calcidiol lower or equal to 80 nmol/l (unsaturated subjects). RESULTS: Statistics include 141 subjects. After a 6-month follow-up, CT imaging and calcidiol levels were performed. PRIMARY OBJECTIVE: postoperative complications in sternotomy were not among the population under or above 80 nmol/l statistical difference (p = 0.907). SECONDARY OBJECTIVES: monitored parameters did not differ between individual arms. But the key was the state of saturation with calcidiol (> 80 nmol/l), which was associated with a significantly lower risk of complete non-healed sternotomy (p = 0.008). CONCLUSION: Optimal calcidiol level (> 80 nmol/l) indicates a positive trend towards greater sternal healing. Cholecalciferol oral administration can be considered as a safe method how to achieve the required calcidiol concentration. TRIAL REGISTRATION: EU Clinical Trials Register, EUDRA CT No: 2016-002606-39.
650    _2
$a lidé $7 D006801
650    12
$a sternotomie $x škodlivé účinky $7 D056346
650    12
$a kardiochirurgické výkony $x škodlivé účinky $7 D006348
650    _2
$a prospektivní studie $7 D011446
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    12
$a hojení ran $x účinky léků $7 D014945
650    _2
$a senioři $7 D000368
650    12
$a kalcifediol $x krev $7 D002112
650    _2
$a lidé středního věku $7 D008875
650    12
$a sternum $x diagnostické zobrazování $x chirurgie $7 D013249
650    _2
$a výsledek terapie $7 D016896
650    _2
$a pooperační komplikace $x etiologie $7 D011183
650    _2
$a časové faktory $7 D013997
650    12
$a cholekalciferol $x aplikace a dávkování $7 D002762
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Čečrle, Michal $u Department of Clinical Pharmacy, Na Homolce Hospital, Prague, Czech Republic $u Institute of Pharmacology, First Faculty of Medicine, Charles University in Prague, Albertov 4, Prague, 12800, Czech Republic $u Department of Occupational Medicine, General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Sedláčková, Eva $u Department of Cardiac Surgery, Na Homolce Hospital, Prague, Czech Republic $u Department of Infectious Diseases, Masaryk Hospital, Usti and Labem, Labem, Czech Republic
700    1_
$a Míková, Barbora $u Department of Radiology, Na Homolce Hospital, Prague, Czech Republic
700    1_
$a Drncová, Eva $u Department of Clinical Biochemistry, Hematology and Immunology, Na Homolce Hospital, Prague, Czech Republic
700    1_
$a Skalský, Ivo $u Department of Cardiac Surgery, Na Homolce Hospital, Prague, Czech Republic
700    1_
$a Mieresová, Marie $u Department of Clinical Pharmacy, Na Homolce Hospital, Prague, Czech Republic $u Department of Pharmacology, Second Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
700    1_
$a Halačová, Milada $u Department of Clinical Pharmacy, Na Homolce Hospital, Prague, Czech Republic $u Department of Pharmacology, Second Faculty of Medicine, Charles University in Prague, Prague, Czech Republic $u Department of Anaesthesia and Intensive Care Medicine, Third Faculty of Medicine, Charles University in Prague and FNKV University Hospital, Prague, Czech Republic
773    0_
$w MED00163187 $t Trials $x 1745-6215 $g Roč. 26, č. 1 (2025), s. 224
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40551234 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731090856 $b ABA008
999    __
$a ok $b bmc $g 2366249 $s 1252398
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 26 $c 1 $d 224 $e 20250623 $i 1745-6215 $m Trials $n Trials $x MED00163187
LZP    __
$a Pubmed-20250708

Find record

Citation metrics

Archiving options